KRM Ayurveda Ltd
KRM Ayurveda Ltd is an Indian pharmaceutical company that develops, manufactures, and markets Ayurvedic and herbal products, primarily for the domestic healthcare market.
Business. KRM Ayurveda Ltd (KRMY.NS) is an Indian healthcare company primarily engaged in the pharmaceuticals industry. The firm is listed on the National Stock Exchange of India and operates within the broader Healthcare Services & Equipment sector. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
KRM Ayurveda Ltd (KRMY.NS) is an Indian healthcare company primarily engaged in the pharmaceuticals industry. The firm is listed on the National Stock Exchange of India and operates within the broader Healthcare Services & Equipment sector. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
KRM Ayurveda operates with a debt-to-equity ratio of 1.31, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.66, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of INR 84.17 million provides some flexibility, though operating cash flow is negative at INR -0.29 million, signaling potential operational inefficiencies.
Profitability metrics show a return on equity (ROE) of 50.67% and a return on assets (ROA) of 18.11%, both significantly above the industry median for Ayurvedic and herbal pharmaceuticals. These figures suggest strong capital efficiency and asset utilization. Gross profit of INR 670.52 million represents 87.6% of revenue, indicating a high-margin business model.
The company's revenue is concentrated in a single business segment focused on Ayurvedic and herbal products, with no disclosed geographic diversification beyond India. This concentration increases exposure to domestic regulatory and economic shifts. No material international revenue is reported, and no segment breakdown is available in the latest filings.
Revenue growth over the past year is not disclosed, but the company's free cash flow and operating income suggest a stable, if not growing, business. The capital expenditure of INR -47.24 million indicates a reduction in investment, which may signal a shift in strategic focus or a response to cash flow constraints.
Risk factors include a negative net cash position after subtracting total debt, which could limit financial flexibility. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. No recent equity issuance or ATM/shelf registration is disclosed in the latest filings.
Recent events include the filing of the latest financial snapshot, which shows a stable but cash-constrained balance sheet. No material earnings call transcripts or regulatory filings are available in the current dataset. The company's focus on Ayurvedic and herbal products aligns with growing consumer interest in traditional medicine, but it remains exposed to regulatory scrutiny and raw material price volatility.
- KRM Ayurveda generates high returns on equity and assets, with ROE of 50.67% and ROA of 18.11%.
- The company's liquidity is moderate, with a current ratio of 1.66 and negative operating cash flow.
- Revenue is concentrated in a single business segment and geographic market, increasing exposure to domestic risks.
- Free cash flow of INR 84.17 million provides some financial flexibility despite negative operating cash flow.
- Dilution risk is low, with no recent equity issuance or material changes in shares outstanding.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- KRM Ayurveda Ltd Market data — financials · 2026-05-28